Curis Lifesciences was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 (Partnership Act) in the name and style of ‘M/s Loreto Pharmaceuticals’, pursuant to a deed of partnership dated June 2, 2010. Thereafter ‘M/s Loreto Pharmaceuticals’ was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of ‘Curis Lifesciences Private Limited’ on March 23, 2016. Subsequently, the company was converted into a public limited company and the name of the company was changed from ‘Curis Lifesciences Private Limited’ to ‘Curis Lifesciences Limited’ vide Special Resolution dated May 6, 2024, the status of the company was changed to public limited and the fresh certificate of incorporation consequent to conversion was issued on August 9, 2024.

It is a pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, etc. It operates in global as well as domestic markets. It undertakes manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. 

The company's business is bifurcated in three catagories such as, in Loan License Manufacturing, all raw materials and excipients are procured and delivered by the client. Further, the client provides the company with necessary supporting documents and formulations. On instructions of the client, the company undertakes manufacturing activities under observation of a chemist, representing the customer.

In Contract Manufacturing, the company would be responsible for procuring and handling all ingredients, raw materials, and packaging materials. Further, all necessary supporting documents and formulations required under manufacturing process would be procured / provided by it. However, the client, is responsible for providing the brand name and product composition. Moreover, all marketing and distribution responsibilities rests with the client. 

In Direct Export/Own Brand Manufacturing, it manufactures products registered by itself in foreign country and sells the said products in foreign country through its distribution network. All ingredients, including raw materials and packaging materials, are purchased and handled by our company. Additionally, we are responsible for all marketing and distribution activities. The brand name and product composition is owned by the company only.

The company is engaged in the pharma manufacturing. It specializes in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, Oral Liquid, etc. It undertakes manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. It operates in global as well as domestic markets.

Products of the company

• Tablet
• Capsule
• External Preparation (Cream/Gel/Ointment)
• Oral Liquid 
• Sterile Ophthalmic Ointment

History and millstones

• 2010-11: Started Business by starting a Partnership Firm with two Partners in name of ‘M/s Loreto Pharmaceutical’ by Dasharathbhai Patel and Piyush Gordhanbhai Antala.
• 2015-16: The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23, 2016.
• 2017-18: The Company received FDA License for manufacturing Pharma products. 
• 2018-19: The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 
• 2019-20: The Company received WHO GMP certificate. 
• 2020-21: The Company received FDA Approval from Philippines during the tragic era of COVID-19 
• 2021-22: Renewal of the WHO Certificates and Nigeria NAFDAC Approval 
• 2022-23: Retention of FDA License for manufacturing Pharma products. 
• 2024-25: Conversion From Private Limited into Public Limited company.